Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and Excretion of [14C]E2086 in Healthy Male Subjects
NCT07308236Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of E2086, sponsored by Eisai Co., Ltd. Primary endpoints: Mass Balance Recovery of E2086, Maximum Observed Concentration and 12 more. Started Dec 2025; status: completed.
02
Drugs
E2086
Beyond the preview
Go deeper on NCT07308236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07308236.